Thus far, the mTOR modulating actions of these inhibitors as monotherapy in cancer have only achieved modest effects as most agents only resulted in stable disease rather than objective response which is typified by tumor regression in most cancers (Carew et al., 2011). Here, MTOR is linked to cancer.